Medical device company Implandata Ophthalmic Products GmbH (Implandata) announced that the first patient in its international, multi-center, clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the suprachoroidally-placed EYEMATE-SC sensor implant for continual monitoring of intraocular pressure (IOP).
Principal investigator, Professor Peter Szurman of the Eye Clinic Sulzbach who performed the implantation of the EYEMATE-SC device in conjunction with non-penetrating glaucoma surgery said, “The new Implandata sensor is pleasantly small and easy to surgically implant; therefore, most patients undergoing glaucoma surgery are likely to be eligible candidates for such a pressure sensor. This breakthrough product enables glaucoma patients for the first time to monitor their own eye pressure at any point in time. I expect that it will improve therapeutic compliance and also significantly reduce the risk of unnecessary visual field loss or even blindness due to glaucoma.”